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Introduction
The importance of vitamin D in a variety of health areas has led to increased interest about
the prevalence, etiologies and associated morbidities of hypovitaminosis D. The role of
vitamin D in absorption of calcium and bone health is well known, but recent data support
additional effects on the immune system, cancer, neuromuscular function, and
cardiovascular system, including hypertension [1,2]. Vitamin D is converted to 25-
hydroxyvitamin D (25-OH D) in the liver and then again to 1,25 dihydroxyvitamin D (1,25-
OH D) in the kidney. While 1,25-OH D is the biologically active form of vitamin D, 25-OH
D is considered the best indicator of vitamin D status in the body because it circulates in a
higher concentration, has a long half-life and is the substrate for 1,25-OH D production [1].
There are several etiologies of vitamin D deficiency and insufficiency (TABLE 1). The lack of
ultraviolet B radiation from sunlight is the most common reason for vitamin D deficiency -
northern latitudes, the winter season, sun protection factors (SPF) in lotions to prevent skin
exposure to the sun all contribute to this form of vitamin D deficiency or insufficiency. The
most common biochemical definition of vitamin D deficiency is a 25-OH D level less than
20 ng/ml (50 nmol/L) while levels from 21 to 29 ng/ml are considered insufficiency [3].
Surveys show that large minorities (40-45%) of elderly Americans and approximately 50%
of post-menopausal women in American are deficient or insufficient in Vitamin D [4].
Prevalence rates go up with increasing age due to lesser quantities of the vitamin D
precursor in the skin, 7-dehydrocholesterol and in populations with high levels of melanin in
the skin (e.g African-Americans and dark-skinned Hispanic populations) since melanin also
impairs the absorption of ultraviolet B radiation (TABLE 1).
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Vitamin D and Cardiovascular Disease
Vitamin D deficiency is associated with diabetes, obesity, metabolic syndrome and
hypertension [5]. In addition, low 25-OH D levels (< 15 to 20 ng/ml) have been associated
with the development of hypertension (6) and cardiovascular events (7). In the Framingham
Offspring Study participants followed for a median interval of 5.4 years demonstrated a
higher relative risk for a cardiovascular event with lower vitamin D levels (FIGURE 1). The risk
of an event increased by 2.13 in subjects with hypertension with 25-OH D levels less than
15 ng/ml [7]. It is impressive that the general risk for cardiovascular disease associated with
vitamin D deficiency is comparable to the Framingham-derived risk ratios if the patient has
metabolic syndrome (relative risk of 2.1), hypertension (relative risk of 1.7), dyslipidemia
(relative risk of 1.8), increased fibrinogen levels (relative risk of 2.42) and homocysteinemia
(relative risk of 1.6) [8-11].
Vitamin D and Hypertension
Epidemiologic association between Vitamin D deficiency and hypertension—
Data from the INTERSALT study suggest a rise in BP is proportional to distance from the
equator [12] while seasonal variations in BP have also been reported in temperate climates
[13]. Population studies have shown an inverse relationship between vitamin D levels and
hypertension, with increasing incidence of hypertension as Vitamin D levels decrease [6,
14]. The largest database is from Forman and colleagues (6) using 117,730 subjects from the
Health Professional follow-up study and the Nurse's Health Studies in which there was a
median follow-up period of 4 years for the development of incident hypertension. When
comparing those individuals whose 25-0H D levels were < 15 ng/ml versus those > 30 ng/
ml, the relative risk of developing hypertension was 3.18, with a marked gender difference
(6.13 in men and 2.67 in women). Hence, a significant inverse relationship exists between
vitamin D and development of hypertension.
Pathophysiologic association of vitamin D and blood pressure—Vitamin D
receptors are ubiquitous in the human body including juxtaglomerular cells in the kidney,
leukocytes, cardiac myocytes and vascular smooth muscle cells (4). The wide distribution of
vitamin D receptors and the 1-alpha-hydroxylase enzyme, which converts 25-OH D to the
physiologically active 1,25-hydroxy vitamin D, suggest widespread action of Vitamin D on
tissue beyond calcium homeostasis. Li et al. [15,16] have demonstrated that vitamin D
deficient (vitamin D receptor-null) mice have plasma renin and angiotensin II levels that are
2.5 times higher than wild-type mice and developed hypertension and cardiac hypertrophy.
Subsequent experiments revealed that vitamin D directly suppresses renin synthesis by
reduction in renin mRNA transcription in the kidney (16). In addition, a recent study by
Kong and coworkers (17) utilizing transgenic mice with human vitamin D receptor positive
renin producing cells showed that vitamin D suppressed renin expression by 30%. This
suppression was also independent of calcium and parathyroid hormone levels. Hence, a
fairly strong link exists between the interplay of vitamin D and suppression of renin release
as well as activation of the renin-angiotensin-aldosterone system with the deficiency of
vitamin D (FIGURE 2).
Animal studies have shown that 1,25-OH Vitamin D improves endothelial dysfunction and
reduces endothelial-derived contracting factors in the aorta [18] and may be related to the
direct binding of vitamin D to vascular endothelial growth factor (VEGF) promoter sites
[19]. There is evidence that vitamin D directly inhibits the proliferation of vascular smooth
muscle cells by altering epidermal growth factor receptor function [20] that may lead to
dysfunction of the arterial media with reduced vascular compliance.
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Clinical studies have shown that increasing 25-OH D levels in patients with diabetes
improves flow-mediated dilation [21]. Data from NHANES III [5] revealed that increases in
25-OH D levels from the range of 6 ng/dL to 28 ng/dL was associated with a reduction in
pulse pressure by nearly 4 mmHg in patients over the age of 50 years. These various types
of basic and clinical evidence suggest that vitamin D may be associated with reductions in
the BP through improvement in arterial compliance.
Treatment effects—There are few intervention studies which have assessed the
relationship between vitamin D replacement and changes in BP (22-24). In an interesting
study by Krause and colleagues (22), the use of thrice weekly ultraviolet B radiation, but not
ultraviolet A radiation, increased 25-OH D levels by 162% and decreased the 24-hour mean
BP by an average of 6/6 mmHg. In the only double-blind randomized trial that has evaluated
the effects of vitamin D on BP, Pfeiffer et al evaluated the effects of 8 weeks of oral calcium
administration compared to oral calcium plus vitamin D3 (800 I.U.) on clinic blood pressure
in 145 women over the age of 70 years [23]. Women with stage 1 systolic hypertension
randomized to calcium alone had a 5.7/6.9 mmHg while those receiving calcium plus
vitamin D fell by 13.1/7.2 mmHg. Patients receiving vitamin D had 25-OH D levels rise
from 25.6 to 64.8 nmol/ml (23). In contrast, an 18-week placebo-controlled study evaluating
1-alpha hydroxyvitamin D showed no changes in BP in 39 patients with stage 1 diastolic
hypertension, however, this patient population was not necessarily vitamin D deficient at
baseline.
Conclusions
With mounting evidence indicating the direct effect of vitamin D on the vascular smooth
muscle cell, endothelial function and the renin-angiotensin-aldosterone system, it is clear
that randomized trials of vitamin D replacement and renin and angiotensin inhibition in
patients with hypertension and vitamin D deficiency are warranted. Preliminary research has
shown an inverse relationship between BP and vitamin D levels, and supplementation
appears promising. To that end, we have just initiated a randomized clinical trial evaluating
the effects of vitamin D and/or a renin inhibitor on ambulatory and clinic BP in vitamin D
deficient patients with hypertension (clinical trials.gov identifier NCT00974922).
The high prevalence of vitamin D deficiency and insufficiency, particularly in northern
latitudes and during the winter months, supports determining 25-hydroxyvitamin D levels in
patients with hypertension and supplementation provided to those whose levels are < 30 ng/
ml. It is noteworthy that recommended 25-OH D levels of > 30 ng/ml (75 nmol/L) are
unlikely to be achieved with the previous recommendation of 200 IU for younger people and
600 IU of vitamin D for older adults [3]. Doses of vitamin D3 from 1000 to 2000 IU daily
are often required [4,25]. For every 100 IU of vitamin D ingested, the levels in patients with
vitamin D deficiency should increase by 1 ng/ml [4]. Therefore, to bring most of the adult
population to levels of > 30 ng/ml, vitamin D supplementation of 1000 IU would be required
in most, but even doses as high as 4,000 I.U. are safe for short-term ‘loading’, and would
bring about 90% of the population to levels above 30 ng/ml within a few weeks.
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Figure 1.
Five-year cardiovascular event rates (%) according to varying levels of 25-hydroxyvitamin
D in the Framingham Offspring Study. Rates were adjusted for age and sex and grouped
according to the presence or absence of hypertension. Modified from reference 7 with
permission.
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Figure 2.
Schema for the relations among vitamin D, vitamin D deficiency, the reninangiotensin-
aldosterone system, and hypertension.
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Table 1
Common Causes of Vitamin D Deficiency
Cause Reason
Age Reduction in precursor of vitamin D (7-dehydrocholesterol) in skin; particularly in individuals >
70 years of age
Chronic liver disease Impaired hydroxylation to 25-hydroxyvitamin D
Chronic renal disease Impaired hydroxylation to 1, 25-dihydroxyvitamin D
Malabsorption Reduced bioavailability of vitamin D
Obesity Increased confiscation of vitamin D in body fat cells
Reduction in ultraviolet light Ultraviolet B (UVB) radiation is required for conversion of 7-dehydrocholesterol to vitamin D3 in
skin; associated with northern latitudes and winter season
Skin pigments (melanin) Melanin absorbs UVB radiation (important in dark-skinned ethnicities)
Sunscreens (sun protection factor 30 or
higher)
Absorbs UVB radiation
*UV - ultraviolet
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